ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1212

Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator

Alex Wessel1, Spiros Vonortas2, Jevgenia Zilberman-Rudenko3, Richard Siegel4 and Eric Hanson5, 15814 Beech Ave, NIH, Bethseda, MD, 2NIH, NIAMS, Bethesda, MD, 3Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4NIAMS, NIH, Bethesda, MD, 5National Institute of Health, Bethesda, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, inflammation and innate immunity

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Signaling Mechanisms

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Behçet’s disease (BD) is a chronic multi-system inflammatory disorder associated clinically with oral and genital ulceration, uveitis, erythema nodosum, and other inflammatory disease. The cause of BD is unknown. A current hypothesis is that an autoinflammatory reaction in individuals with a permissive genotype may arise due to altered cellular signal transduction events and hence altered immune cell function. This reaction may be triggered in these individuals due to infectious agents or microbes not generally considered pathogenic. The family of NF-kB transcription factors are activated in various  signaling pathways involved in microbial sensing, immunity, and inflammatory disease. Previously, a case of familial Behcets was described in two females harboring a mutation in the C-termial Zinc finger domain of NEMO, the NF-kB essential modulator, a key regulator of NF-kB activation.

Methods:

We evaluated female patients diagnosed with Behcets disease who harbor mutation in the NEMO C-terminus, in addition to those with mutation affecting another ubiquitin binding domain. Patient mononuclear cells in addition to patient-mutation-reconstituted NF-kB reporter T cell lines were stimulated with TNF, Toll-like Receptor (TLR) ligands Flagellin and LPS, in addition to anti-CD3/CD28, and PMA/Ionomycin. Gene expression, cytokine production and biochemical assays including co-immunoprecipitation of endogenous proteins implicated in the regulation of NF-kB activation were performed to characterize signaling and cellular responses.

Results:

Mutation leading to premature truncation of the C-terminal Zinc finger in females is associated with a BD phenotype. NF-kB activation by reporter assay in cells harboring the patient mutation reveals enhanced NF-kB activation in response to TNF and TLR5 stimulation compared to the response seen in cells harboring other NEMO mutation not associated with BD. Cytokine production by capture assay indicates LPS induced IL-1b, TNF and GMCSF were approximately 2-fold increased compared to unrelated control, whereas other cytokine responses were normal or reduced. Co-immunoprecipitation studies following cell stimulation with TNF reveal impaired stabilization of the NF-kB negative regulator A20 at the receptor in cells harboring the patient mutation.

Conclusion:

These results illustrate that single gene defects may lead to phenotypes observed in complex genetic disease.  Molecular characterization of the altered signaling resulting from NEMO mutation may yield important insights into more common rheumatic disease such as BD.


Disclosure:

A. Wessel,
None;

S. Vonortas,
None;

J. Zilberman-Rudenko,
None;

R. Siegel,
None;

E. Hanson,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-in-females-due-to-mutation-in-nemo-the-nf-kb-essential-modulator/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology